The FDA, under Commissioner Martin Makary, has launched a pilot commissioner’s national priority voucher program designed to shorten review times for biotech drugs by one to two months. The initiative responds to pressures to maintain competitiveness with global markets like China and promises to expedite early-stage clinical trial approvals and regulatory assessments. This move signals a paradigm shift toward increased regulatory agility to support innovation and timely patient access to novel therapies.